https://www.selleckchem.com/pr....oducts/azd0156-azd-0
BCC. It confirms the transferability of the results of the pivotal trial into routine clinical practice.Several therapeutic regimens, including neoadjuvant chemoradiation therapy (NACRT), have been reported to serve as anticancer immune effectors. However, there remain insufficient data regarding the immune response after NACRT in pancreatic ductal adenocarcinoma (PDAC) patients. Data from 40 PDAC patients that underwent surgical resection after NACRT (NACRT group) and 30 PDAC patients that underwent upfront surgery (US group)
Mi piace
Commento
Condividi
